Eli Lilly plans to acquire three vaccine developers
The acquisition, which is expected to be finalized by the end of Q1 2024, includes companies known for their work on various vaccine candidates, including those targeting infectious diseases and emerging viral threats. By integrating these firms, Eli Lilly aims to bolster its research and development efforts, leveraging new technologies and expertise. This strategic acquisition … Read more